| Species |
Human |
| Protein Construction |
TIGIT (Met22-Pro141)_x000D_
Accession # Q495A1-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by SECHPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TIGIT hFc Chimera, Human at 1μg/ml (100μl/well) on the plate can bind Human CD155, mFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
39.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
TIGIT, also called Vstm3, Vsig9, and WUCAM, is a transmembrane protein in the CD28 family of the Ig superfamily proteins.IGIT is expressed at low levels on peripheral memory and regulatory CD4 T-cells and NK cells and is up-regulated following activation of these cells. |
| Synonyms |
TIGIT; VSIG9; VSTM3; WUCAM |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
